|
 The combination of the company's Empliciti, Celgene Corp's Revlimid
and common anti-inflammatory drug dexamethasone failed to show
statistically significant results, in comparison to a combination of
Revlimid and dexamethasone.
Bristol Myers gained access to Revlimid through its $74 billion
buyout of Celgene last year.
Shares of Bristol Myers were trading down 4.7% at $57.50 premarket,
amid broader market weakness after Saudi Arabia launched a price war
with Russia and the ongoing coronavirus outbreak.
The triple combination from Bristol Myers was first approved in 2015
for treating patients whose cancer had relapsed or those who did not
respond to available therapies. Empliciti was co-developed with
drugmaker AbbVie Inc.
[to top of second column] |
Bristol Myers said although it was disappointed with the initial study results,
it would complete a full evaluation of the data and present results at a future
medical meeting.
Multiple myeloma is a form of cancer that starts in plasma cells in bone marrow
and ultimately disrupts the production of normal blood cells.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
